Exploring brain activity changes in treatment-resistant depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how working memory and reward markers influence brain activity in the dorsolateral prefrontal cortex (DLPFC) of individuals with treatment-resistant major depressive disorder (MDD). Participants will undergo repetitive transcranial magnetic stimulation (rTMS), a non-invasive procedure that uses magnetic fields to stimulate specific brain areas, alongside assessments through interviews, questionnaires, brain scans, and saliva samples. The goal is to better understand the mechanisms by which rTMS alleviates depressive symptoms in patients who have not responded to traditional treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Depressed Participants:

1. Between the ages of 18 and 65 years old.
2. Capable of giving voluntary and informed consent.
3. Fluent in English.
4. Meet Diagnostic and Statistical Manual criteria for single or recurrent Major Depressive Disorder (current major depressive episode), confirmed via the Mini-International Neuropsychiatric Interview (MINI).
5. Moderate to severe depression severity, defined as a 17-item Hamilton Depression Rating Scale260 score ≥ 18.
6. Have failed to achieve a clinical response to an adequate dose of an antidepressant based in an Antidepressant Treatment History Form (ATHF) score ≥ 3 in the current episode, or have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (AHTF = 1 or 2)
7. Have had no initiation or dose change in any psychotropic medication in the four weeks prior to screening.
8. If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study.
9. Can adhere to the study schedule.

Nondepressed Participants:

1. Between the ages of 18 and 65 years old.
2. Capable of giving voluntary and informed consent.
3. Fluent in English.
4. No current or previous history of psychiatric diagnoses.
5. Absent/non-clinical depression severity, defined as a 17-item Hamilton Depression Rating Scale260 \< 8.
6. No history of antidepressant use, as measured by the ATHF.

Exclusion Criteria:

All Participants:

1. Are pregnant/lactating.
2. Acute suicidality, defined as a score \>3 on the 17-item Hamilton Depression Rating Scale, Item #3.
3. A MINI-confirmed diagnosis of bipolar disorder, or another comorbidity (e.g., obsessive-compulsive disorder, post-traumatic stress disorder) that is primary in severity and disability relative to their MDD.
4. Other major medical comorbidities requiring immediate investigation or treatment, cardiac pacemaker, or implanted medication pump.
5. Lifetime history of psychosis, including schizophrenia, schizoaffective disorder, delusional disorder, or current psychotic symptoms.
6. Drug abuse or dependence within the last 6 months, excluding caffeine and nicotine.
7. Contraindication to receiving the rTMS (e.g. history of seizure, cochlear implants, benzodiazepine use (lorazepam or equivalent daily dose \>2mg daily), cardiac pacemaker, implanted neurostimulator, significant head trauma with loss of consciousness for greater than or equal to 5 minutes).
8. Electroconvulsive therapy (ECT) within the current depressive episode.
9. Presence of contraindications for MRI, including metallic implants.
10. Have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, dementia, significant head trauma with loss of consciousness for greater than or equal to 5 minutes.

Where it's running

• Unity Health Toronto
  Toronto, Ontario, Canada Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mindfulness‑augmented brain stimulation for treatment‑resistant depression

  This trial will test whether combining fast brain stimulation (iTBS) with a digital mindfulness program helps people with treatment‑resistant depression reduce symptoms and improve thinking.

  Recruiting Phase 2 University of California, San Diego · San Diego, California · NCT07512284

• Adding ketamine to ECT for treatment-resistant depression

  This trial will test whether giving IV ketamine during ECT helps adults with treatment-resistant major depression get better faster and have fewer thinking problems.

  Recruiting Phase 3 Università Vita-Salute San Raffaele · Milan · NCT07088380

• Maintenance treatment using rTMS for depression

  This study is testing if a type of brain treatment called rTMS can help people with hard-to-treat depression stay feeling better after their initial treatment.

  Recruiting at 3 sites University of California, San Diego · San Diego, California and 2 other locations · NCT06938841

• Identifying brain biomarkers for treatment-resistant major depression using deep brain stimulation

  This study is testing if deep brain stimulation can help people with severe depression who haven't found relief from regular treatments by looking for brain signals that could predict their mood changes.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT06542094

• Using gamma oscillations to predict ketamine therapy outcomes in depression

  This study is testing if brain activity measured during ketamine treatment can help predict how well it will work for people with depression that hasn't responded to other treatments.

  Recruiting at 2 sites Phase 1 Texas A&M University · Houston, Texas and 1 other locations · NCT06480201

• Understanding the impact of mood disorders and treatment responses

  This study is trying to learn more about how people with depression and bipolar disorder respond to treatment by talking to them weekly for up to 12 weeks to improve future care and predict how well medications might work.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06462196

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.